Status:
COMPLETED
Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together
Lead Sponsor:
Avexa
Conditions:
HIV Infection
Eligibility:
MALE
18-40 years
Phase:
PHASE1
Brief Summary
The aim of the study is to see if apricitabine or tipranavir affect the levels of each other in the blood (pharmacokinetic interaction) when they are dosed together.
Detailed Description
Apricitabine is a new NRTI in development for treatment of drug resistant HIV. Tipranavir is a recently licensed protease inhibitor for treatment of drug resistant HIV. Tipranavir affects the plasma c...
Eligibility Criteria
Inclusion
- healthy males 18-40 years old
- non-smokers
- no clinically significant medical history
Exclusion
- current or relevant previous medical history of significance
- hepatitis B, hepatitis C, or HIV positive
- current use of prescription or OTC medications
- use of illicit substances or alcohol (\>14 drinks/week)
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2006
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00352066
Start Date
July 1 2006
End Date
August 1 2006
Last Update
June 23 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jasper Clinic Inc
Kalamazoo, Michigan, United States, 49007